Baytacare Pharmaceutical Co., Ltd. provided that the group is expected to record a net loss for the year ended 31 December 2017 as compared with a net profit for the same period of the previous year. The expected loss for the year ended 31 December 2017 is mainly attributable to the followings: a decrease in revenue of the Group of approximately 42.06%; impairment loss of trade receivables; impairment loss for the receivables from a third party; and the increase in the administrative expenses and deferred tax charges arising from fair value gain in investment properties.